The Weight-Loss Gold Rush: Legal and Regulatory Implications

Jul 11, 10:00 AM

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market